EGFR and neoplasm: Moreover, in this proof-of-concept prospective trial of liquid biopsy monitoring, we demonstrated for the first time that a continued wt circulating mutation status is a valuable biomarker of a prolonged tumor response to anti-EGFR therapy, while mutation explosion events predicted an eminent clinical deterioration in mCRC patients.